Histogenics Corporation Company Profile (NASDAQ:HSGX)

Histogenics Corporation trades on the NASDAQ under the ticker symbol "HSGX."

Histogenics Corporation (NASDAQ:HSGX) announced its earnings results on Thursday, May, 11th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.34) by $0.07. During the same period last year, the business earned ($0.60) earnings per share. View Histogenics Corporation's Earnings History.

5 analysts have issued 1 year target prices for Histogenics Corporation's shares. Their forecasts range from $3.50 to $11.00. On average, they expect Histogenics Corporation's share price to reach $5.88 in the next twelve months. View Analyst Ratings for Histogenics Corporation.

Here are some recent quotes from research analysts about Histogenics Corporation stock:

• 1. According to Zacks Investment Research, "Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. " (5/16/2017)
• 2. Canaccord Genuity analysts commented, "We maintain our BUY rating following the Q1/17 results. Histogenics reported zero revenues and a diluted net loss of $5.8M, compared to CG/consensus of $7.5M/$6.9M net loss, and LPS of $(0.27), in line with CG/consensus estimate of $(0.27). Histogenics provided numerous clinical trial metrics to demonstrate to investors the improved momentum of enrollment in the NeoCart Phase 3 trial. Specifically, trial enrollment, as of the Q1/17 call, stands at 230 patients out of 245 total, and up from 214 as of the Q4/16 call, and just 15 shy of complete trial enrollment. Management reiterated its expectation to complete enrollment by Q2/17 and already has 15 additional patients who have consented to the trial with more patients in the pipeline if needed. Management indicated they would announce completed enrollment in early July 2017." (5/11/2017)

Histogenics Corporation saw a increase in short interest in May. As of May 15th, there was short interest totalling 95,242 shares, an increase of 19.4% from the April 28th total of 79,740 shares. Based on an average trading volume of 80,387 shares, the days-to-cover ratio is presently 1.2 days.

Some companies that are related to Histogenics Corporation include Diurnal Group PLC (DNL), Concordia International Corp. (CXRX), Innocoll Holdings (INNL), Neuralstem (CUR), Intellipharmaceutics International (IPCI), Amryt Pharma PLC (AMYT), Juniper Pharmaceuticals (JNP), SCYNEXIS (SCYX), Pernix Therapeutics Holdings (PTX), Evoke Pharma (EVOK), Marinus Pharmaceuticals (MRNS), Immune Pharmaceuticals (IMNP), Venture Life Group PLC (VLG), Galena Biopharma (GALE), Eyegate Pharmaceuticals (EYEG), Apricus Biosciences (APRI), Aegerion Pharmaceuticals (AEGR) and Amryt Pharma PLC (FAST).

Histogenics Corporation's management team includes the folowing people:

• Garheng Kong M.D. Ph.D., Independent Chairman of the Board
• Adam Gridley, President, Chief Executive Officer, Director
• Jonathan I. Lieber, Chief Financial Officer
• Stephen Richard Kennedy, Chief Technology Officer
• Gloria Matthews Ph.D., Chief Medical Officer
• Joshua J. Baltzell, Independent Director
• David N. Gill, Independent Director
• John H. Johnson, Independent Director
• Michael Lewis, Independent Director
• Kevin L. Rakin, Independent Director

(HSGX) raised $60 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Histogenics Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include Third Security LLC (13.03%), Sofinnova Management VIII L.L.C. (10.06%), Perceptive Advisors LLC (8.61%), FMR LLC (8.38%), Sabby Management LLC (5.31%) and Palo Alto Investors LLC (1.47%). Company insiders that own Histogenics Corporation stock include Adam Gridley, David N Gill, Jonathan I Lieber and Split Rock Partners Ii, Lp. View Institutional Ownership Trends for Histogenics Corporation.

Histogenics Corporation's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Histogenics Corporation.

Histogenics Corporation's stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Sabby Management LLC and Carl Domino Inc. Company insiders that have bought Histogenics Corporation stock in the last two years include Adam Gridley, David N Gill, Jonathan I Lieber and Split Rock Partners Ii, Lp. View Insider Buying and Selling for Histogenics Corporation.

Shares of Histogenics Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Histogenics Corporation stock can currently be purchased for approximately $1.80.